{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T11:43:32Z","timestamp":1792410212976,"version":"4.4.0"},"reference-count":59,"publisher":"Siapec Servizi Srl","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathologica"],"DOI":"10.32074\/1591-951x-747","type":"journal-article","created":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T08:04:42Z","timestamp":1649837082000},"page":"104-110","source":"Crossref","is-referenced-by-count":11,"title":["Pathological examination of breast cancer samples before and after neoadjuvant therapy: recommendations from the Italian Group for the Study of Breast Pathology - Italian Society of Pathology (GIPaM-SIAPeC)"],"prefix":"10.32074","volume":"114","author":[{"given":"Nicola","family":"Fusco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leopoldo","family":"Costarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Santinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna","family":"Cerbelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Scatena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ettore","family":"Macr\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Pietribiasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"d\u2019Amati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sapino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"21774","published-online":{"date-parts":[[2022,4]]},"reference":[{"key":"10.32074\/1591-951X-747_ref1","doi-asserted-by":"crossref","unstructured":"Redden MH, Fuhrman GM. Neoadjuvant chemotherapy in the treatment of breast cancer. Surg Clin North Am 2013;93:493-499. https:\/\/doi.org\/10.1016\/j.suc.2013.01.006","DOI":"10.1016\/j.suc.2013.01.006"},{"key":"10.32074\/1591-951X-747_ref2","unstructured":"National Comprehensive Cancer Network. NCNN Clinical Practice Guidelines in Oncology - Breast Cancer Version 4.2020."},{"key":"10.32074\/1591-951X-747_ref3","doi-asserted-by":"crossref","unstructured":"Greenwell K, Hussain L, Lee D, et al. Complete pathologic response rate to neoadjuvant chemotherapy increases with increasing HER2\/CEP17 ratio in HER2 overexpressing breast cancer: analysis of the National Cancer Database (NCDB). Breast cancer research and treatment 2020;181:249-254. https:\/\/doi.org\/10.1007\/s10549-020-05599-1","DOI":"10.1007\/s10549-020-05599-1"},{"key":"10.32074\/1591-951X-747_ref4","unstructured":"Franceschini G, Di Leone A, Natale M, et al. Conservative surgery after neoadjuvant chemotherapy in patients with operable breast cancer. Ann Ital Chir 2018;89:290."},{"key":"10.32074\/1591-951X-747_ref5","doi-asserted-by":"crossref","unstructured":"Curigliano G, Burstein HJ, Winer EP, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 2017;28:1700-1712. https:\/\/doi.org\/10.1093\/annonc\/mdx308","DOI":"10.1093\/annonc\/mdx308"},{"key":"10.32074\/1591-951X-747_ref6","doi-asserted-by":"crossref","unstructured":"Labrosse J, Osdoit M, Hamy A-S, et al. Adjuvant chemotherapy for breast cancer after preoperative chemotherapy: A propensity score matched analysis. PLOS ONE 2020;15:e0234173. https:\/\/doi.org\/10.1371\/journal.pone.0234173","DOI":"10.1371\/journal.pone.0234173"},{"key":"10.32074\/1591-951X-747_ref7","doi-asserted-by":"crossref","unstructured":"Bartsch R, Bergen E, Galid A. Current concepts and future directions in neoadjuvant chemotherapy of breast cancer. Memo 2018;11:199-203. https:\/\/doi.org\/10.1007\/s12254-018-0421-1","DOI":"10.1007\/s12254-018-0421-1"},{"key":"10.32074\/1591-951X-747_ref8","doi-asserted-by":"crossref","unstructured":"Invernizzi M, Kim J, Fusco N. Editorial: Quality of life in breast cancer patients and survivors. Frontiers in Oncology 2020;10:620574. https:\/\/doi.org\/10.3389\/fonc.2020.620574","DOI":"10.3389\/fonc.2020.620574"},{"key":"10.32074\/1591-951X-747_ref9","doi-asserted-by":"crossref","unstructured":"Dieci MV, Radosevic-Robin N, Fineberg S, et al. Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: a report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. Semin Cancer Biol 2018;52:16-25. https:\/\/doi.org\/10.1016\/j.semcancer.2017.10.003","DOI":"10.1016\/j.semcancer.2017.10.003"},{"key":"10.32074\/1591-951X-747_ref10","doi-asserted-by":"crossref","unstructured":"Hamy AS, Lam GT, Laas E, et al. Lymphovascular invasion after neoadjuvant chemotherapy is strongly associated with poor prognosis in breast carcinoma. Breast Cancer Res Treat 2018;169:295-304. https:\/\/doi.org\/10.1007\/s10549-017-4610-0","DOI":"10.1007\/s10549-017-4610-0"},{"key":"10.32074\/1591-951X-747_ref11","doi-asserted-by":"crossref","unstructured":"Invernizzi M, Corti C, Lopez G, et al. Lymphovascular invasion and extranodal tumour extension are risk indicators of breast cancer related lymphoedema: an observational retrospective study with long-term follow-up. BMC cancer 2018;18:935. https:\/\/doi.org\/10.1186\/s12885-018-4851-2","DOI":"10.1186\/s12885-018-4851-2"},{"key":"10.32074\/1591-951X-747_ref12","doi-asserted-by":"crossref","unstructured":"Korde LA, Somerfield MR, Carey LA, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO Guideline. J Clin Oncol 2021;Jco2003399. https:\/\/doi.org\/10.1200\/jco.20.03399","DOI":"10.1200\/JCO.20.03399"},{"key":"10.32074\/1591-951X-747_ref13","doi-asserted-by":"crossref","unstructured":"Yau C, Osdoit M, van der Noordaa M, et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol 2022;23:149-160. https:\/\/doi.org\/10.1016\/S1470-2045(21)00589-1. Epub 2021 Dec 11.","DOI":"10.1016\/S1470-2045(21)00589-1"},{"key":"10.32074\/1591-951X-747_ref14","doi-asserted-by":"crossref","unstructured":"Cerbelli B, Botticelli A, Pisano A, et al. Breast cancer subtypes affect the nodal response after neoadjuvant chemotherapy in locally advanced breast cancer: Are we ready to endorse axillary conservation? Breast J 2019;25:273-277. https:\/\/doi.org\/10.1111\/tbj.13206","DOI":"10.1111\/tbj.13206"},{"key":"10.32074\/1591-951X-747_ref15","doi-asserted-by":"crossref","unstructured":"Viale G, Fusco N. Pathology after neoadjuvant treatment - How to assess residual disease. Breast 2021;S0960-9776(21)00990-5. https:\/\/doi.org\/10.1016\/j.breast.2021.11.009","DOI":"10.1016\/j.breast.2021.11.009"},{"key":"10.32074\/1591-951X-747_ref16","doi-asserted-by":"crossref","unstructured":"Guerini-Rocco E, Botti G, Foschini MP, et al. Role and evaluation of pathologic response in early breast cancer specimens after neoadjuvant therapy: consensus statement. Tumori 2021;3008916211062642. https:\/\/doi.org\/10.1177\/03008916211062642","DOI":"10.1177\/03008916211062642"},{"key":"10.32074\/1591-951X-747_ref17","doi-asserted-by":"crossref","unstructured":"Angerilli V, Galuppini F, Pagni F, et al. The role of the pathologist in the next-generation era of tumor molecular characterization. 2021;11:339. https:\/\/doi.org\/10.3390\/diagnostics11020339","DOI":"10.3390\/diagnostics11020339"},{"key":"10.32074\/1591-951X-747_ref18","doi-asserted-by":"crossref","unstructured":"Berrino E, Annaratone L, Miglio U, et al. Cold formalin fixation guarantees DNA Integrity in formalin fixed paraffin embedded tissues: premises for a better quality of diagnostic and experimental pathology with a specific impact on breast cancer. Fron Oncol 2020;10:173. https:\/\/doi.org\/10.3389\/fonc.2020.00173","DOI":"10.3389\/fonc.2020.00173"},{"key":"10.32074\/1591-951X-747_ref19","unstructured":"Fusco N, Ragazzi M, Sajjadi E, et al. Assessment of estrogen receptor low positive status in breast cancer: implications for pathologists and oncologists. Histol Histopathol 2021;36:1235-1245. https:\/\/doi.org\/10.14670\/hh-18-376"},{"key":"10.32074\/1591-951X-747_ref20","doi-asserted-by":"crossref","unstructured":"Lester SC. Manual of surgical pathology Philadelphia: Elsevier Saunders 2010.","DOI":"10.1016\/B978-0-323-06516-0.10004-9"},{"key":"10.32074\/1591-951X-747_ref21","unstructured":"WHO Classification of Tumours Editorial Board. Breast Tumours: WHO Classification of Tumours 2019. 5th ed. Vol. 2. Lyon: IARC Press 2019."},{"key":"10.32074\/1591-951X-747_ref22","doi-asserted-by":"crossref","unstructured":"Cserni G. Histological type and typing of breast carcinomas and the WHO classification changes over time. Pathologica 2020;112:25-41. https:\/\/doi.org\/10.32074\/1591-951x-1-20","DOI":"10.32074\/1591-951X-1-20"},{"key":"10.32074\/1591-951X-747_ref23","doi-asserted-by":"crossref","unstructured":"Rakha EA, Reis-Filho JS, Baehner F, et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast cancer research: BCR 2010;12:207. https:\/\/doi.org\/10.1186\/bcr2607","DOI":"10.1186\/bcr2607"},{"key":"10.32074\/1591-951X-747_ref24","doi-asserted-by":"crossref","unstructured":"Cardoso F, Cataliotti L, Costa A, et al. European Breast Cancer Conference manifesto on breast centres\/units. Eur J Cancer 2017;72:244-250. https:\/\/doi.org\/10.1016\/j.ejca.2016.10.023","DOI":"10.1016\/j.ejca.2016.10.023"},{"key":"10.32074\/1591-951X-747_ref25","doi-asserted-by":"crossref","unstructured":"Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2013. Ann Oncol 2013;24:2206-2223. https:\/\/doi.org\/10.1093\/annonc\/mdt303","DOI":"10.1093\/annonc\/mdt303"},{"key":"10.32074\/1591-951X-747_ref26","doi-asserted-by":"crossref","unstructured":"Bussolati G, Annaratone L, Maletta F. The pre-analytical phase in surgical pathology. Recent Results Cancer Res 2015;199:1-13. https:\/\/doi.org\/10.1007\/978-3-319-13957-9_1","DOI":"10.1007\/978-3-319-13957-9_1"},{"key":"10.32074\/1591-951X-747_ref27","doi-asserted-by":"crossref","unstructured":"Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO\/CAP Guideline Update. J Clin Oncol 2020;38:1346-1366. https:\/\/doi.org\/10.1200\/jco.19.02309","DOI":"10.1200\/JCO.19.02309"},{"key":"10.32074\/1591-951X-747_ref28","doi-asserted-by":"crossref","unstructured":"Costarelli L, Rizzo A, Bortul M, et al. Pre-analytics, a national survey of Senonetwork Italia breast centers: Much still to do ahead. European Journal of Surgical Oncology 2021;47:240-244. https:\/\/doi.org\/10.1016\/j.ejso.2020.08.029","DOI":"10.1016\/j.ejso.2020.08.029"},{"key":"10.32074\/1591-951X-747_ref29","doi-asserted-by":"crossref","unstructured":"Bossuyt V, Provenzano E, Symmans WF, et al. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. Ann Oncol 2015;26:1280-1291. https:\/\/doi.org\/10.1093\/annonc\/mdv161","DOI":"10.1093\/annonc\/mdv161"},{"key":"10.32074\/1591-951X-747_ref30","doi-asserted-by":"crossref","unstructured":"Guerini-Rocco E, Fusco N. Premalignant and preinvasive lesions of the breast. In: Veronesi U, Goldhirsh A, Veronesi P, et al., eds. Breast cancer: innovations in research and management. Springer International Publishing 2017, Vol. 1, pp. 103-120.","DOI":"10.1007\/978-3-319-48848-6_11"},{"key":"10.32074\/1591-951X-747_ref31","doi-asserted-by":"crossref","unstructured":"Cortazar P, Geyer CE. Pathological complete response in neoadjuvant treatment of breast cancer. Ann Surg Oncol 2015;22:1441-1446. https:\/\/doi.org\/10.1245\/s10434-015-4404-8","DOI":"10.1245\/s10434-015-4404-8"},{"key":"10.32074\/1591-951X-747_ref32","doi-asserted-by":"crossref","unstructured":"Potter DA, Herrera-Ponzanelli CA, Hinojosa D, et al. Recent advances in neoadjuvant therapy for breast cancer. Fac Rev 2021;10:2. https:\/\/doi.org\/10.12703\/r\/10-2","DOI":"10.12703\/r\/10-2"},{"key":"10.32074\/1591-951X-747_ref33","doi-asserted-by":"crossref","unstructured":"Viale G. Characterization and clinical impact of residual disease after neoadjuvant chemotherapy. Breast 2013;22:S88-S91. https:\/\/doi.org\/10.1016\/j.breast.2013.07.016","DOI":"10.1016\/j.breast.2013.07.016"},{"key":"10.32074\/1591-951X-747_ref34","doi-asserted-by":"crossref","unstructured":"Man V, Kwong A. Different strategies in marking axillary lymph nodes in breast cancer patients undergoing neoadjuvant medical treatment: a systematic review. Breast Cancer Res Treat 2021;186:607-615. https:\/\/doi.org\/10.1007\/s10549-021-06118-6","DOI":"10.1007\/s10549-021-06118-6"},{"key":"10.32074\/1591-951X-747_ref35","unstructured":"Fitzgibbons P, Connolly J, Bose S, Pathologists, C.o.A. Protocol for the examination of resection specimens from patients with invasive carcinoma of the breast. College of American Pathologists. Version: Breast Invasive Resection 2020;4.4.0."},{"key":"10.32074\/1591-951X-747_ref36","doi-asserted-by":"crossref","unstructured":"Michelotti A, Invernizzi M, Lopez G, et al. Tackling the diversity of breast cancer related lymphedema: perspectives on diagnosis, risk assessment, and clinical management. Breast 2019;44:15-23. https:\/\/doi.org\/10.1016\/j.breast.2018.12.009","DOI":"10.1016\/j.breast.2018.12.009"},{"key":"10.32074\/1591-951X-747_ref37","doi-asserted-by":"crossref","unstructured":"Racz JM, Caudle AS. Sentinel node lymph node surgery after neoadjuvant therapy: principles and techniques. Ann Surg Oncol 2019;26:3040-3045. https:\/\/doi.org\/10.1245\/s10434-019-07591-6","DOI":"10.1245\/s10434-019-07591-6"},{"key":"10.32074\/1591-951X-747_ref38","doi-asserted-by":"crossref","unstructured":"Caudle AS, Yang WT, Krishnamurthy S, et al. Improved Axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol 2016;34:1072-1078. https:\/\/doi.org\/10.1200\/jco.2015.64.0094","DOI":"10.1200\/JCO.2015.64.0094"},{"key":"10.32074\/1591-951X-747_ref39","doi-asserted-by":"crossref","unstructured":"Geng C, Chen X, Pan X, et al. The Feasibility and accuracy of sentinel lymph node biopsy in initially clinically node-negative breast cancer after neoadjuvant chemotherapy: a systematic review and meta-analysis. PLoS One 2016;11:e0162605. https:\/\/doi.org\/10.1371\/journal.pone.0162605","DOI":"10.1371\/journal.pone.0162605"},{"key":"10.32074\/1591-951X-747_ref40","doi-asserted-by":"crossref","unstructured":"Fu J-F, Chen H-L, Yang J, et al. Feasibility and accuracy of sentinel lymph node biopsy in clinically node-positive breast cancer after neoadjuvant chemotherapy: a meta-analysis. PLoS One 2014;9:e105316. https:\/\/doi.org\/10.1371\/journal.pone.0105316","DOI":"10.1371\/journal.pone.0105316"},{"key":"10.32074\/1591-951X-747_ref41","doi-asserted-by":"crossref","unstructured":"Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol 2015;33:258-264. https:\/\/doi.org\/10.1200\/jco.2014.55.7827","DOI":"10.1200\/JCO.2014.55.7827"},{"key":"10.32074\/1591-951X-747_ref42","unstructured":"Wapnir IL, Khan A. Current strategies for the management of locoregional breast cancer recurrence. Oncology (Williston Park) 2019;33:19-25."},{"key":"10.32074\/1591-951X-747_ref43","doi-asserted-by":"crossref","unstructured":"Shigematsu H, Ozaki S, Yasui D, et al. Comparison of CK-IHC assay on serial frozen sections, the OSNA assay, and in combination for intraoperative evaluation of SLN metastases in breast cancer. Breast Cancer 2018;25:191-197. https:\/\/doi.org\/10.1007\/s12282-017-0811-y","DOI":"10.1007\/s12282-017-0811-y"},{"key":"10.32074\/1591-951X-747_ref44","doi-asserted-by":"crossref","unstructured":"Gandhi A, Coles C, Makris A, et al. Axillary surgery following neoadjuvant chemotherapy - Multidisciplinary guidance from the Association of Breast Surgery, Faculty of Clinical Oncology of the Royal College of Radiologists, UK Breast Cancer Group, National Coordinating Committee for Breast Pathology and British Society of Breast Radiology. Clin Oncol (R Coll Radiol) 2019;31:664-668. https:\/\/doi.org\/10.1016\/j.clon.2019.05.021","DOI":"10.1016\/j.clon.2019.05.021"},{"key":"10.32074\/1591-951X-747_ref45","doi-asserted-by":"crossref","unstructured":"Gooch J, King TA, Eaton A, et al. The extent of extracapsular extension may influence the need for axillary lymph node dissection in patients with T1-T2 breast cancer. Ann Surg Oncol 2014;21:2897-2903. https:\/\/doi.org\/10.1245\/s10434-014-3752-0","DOI":"10.1245\/s10434-014-3752-0"},{"key":"10.32074\/1591-951X-747_ref46","doi-asserted-by":"crossref","unstructured":"Nottegar A, Veronese N, Senthil M, et al. Extra-nodal extension of sentinel lymph node metastasis is a marker of poor prognosis in breast cancer patients: a systematic review and an exploratory meta-analysis. Eur J Surg Oncol 2016;42:919-925. https:\/\/doi.org\/10.1016\/j.ejso.2016.02.259","DOI":"10.1016\/j.ejso.2016.02.259"},{"key":"10.32074\/1591-951X-747_ref47","doi-asserted-by":"crossref","unstructured":"Pinder SE, Rakha EA, Purdie CA, et al. Macroscopic handling and reporting of breast cancer specimens pre- and post-neoadjuvant chemotherapy treatment: review of pathological issues and suggested approaches. Histopathology 2015;67:279-293. https:\/\/doi.org\/10.1111\/his.12649","DOI":"10.1111\/his.12649"},{"key":"10.32074\/1591-951X-747_ref48","unstructured":"MD Anderson Cancer Center - Breast Cancer Residual Cancer Burden Calculator, Pathologic Evaluation of RCB in Breast Specimens. Available online: https:\/\/www.mdanderson.org\/for-physicians\/clinical-tools-resources\/clinical-calculators\/residual-cancer-burden.html (accessed on 27\/09\/2021)."},{"key":"10.32074\/1591-951X-747_ref49","doi-asserted-by":"crossref","unstructured":"Penault-Llorca F, Radosevic-Robin N. Biomarkers of residual disease after neoadjuvant therapy for breast cancer. Nat Rev Clin Oncol 2016;13:487-503. https:\/\/doi.org\/10.1038\/nrclinonc.2016.1","DOI":"10.1038\/nrclinonc.2016.1"},{"key":"10.32074\/1591-951X-747_ref50","unstructured":"The American Society of Breast Surgeons, Consensus Guideline on the Management of the Axilla in Patients With Invasive\/In-Situ Breast Cancer. 2019."},{"key":"10.32074\/1591-951X-747_ref51","doi-asserted-by":"crossref","unstructured":"Moo TA, Edelweiss M, Hajiyeva S, et al. Is low-volume disease in the sentinel node after neoadjuvant chemotherapy an indication for axillary dissection? Ann Surg Oncol 2018;25:1488-1494. https:\/\/doi.org\/10.1245\/s10434-018-6429-2","DOI":"10.1245\/s10434-018-6429-2"},{"key":"10.32074\/1591-951X-747_ref52","doi-asserted-by":"crossref","unstructured":"Cavalcante FP, Millen EC, Zerwes FP, et al. Role of Axillary surgery after neoadjuvant chemotherapy. JCO Glob Oncol 2020;6:238-241. https:\/\/doi.org\/10.1200\/jgo.19.00351","DOI":"10.1200\/JGO.19.00351"},{"key":"10.32074\/1591-951X-747_ref53","doi-asserted-by":"crossref","unstructured":"Blundo C, Giroda M, Fusco N, et al. Early Breast Cancers during pregnancy treated with breast-conserving surgery in the first trimester of gestation: A feasibility study. Front Oncol 2021;11:723693. https:\/\/doi.org\/10.3389\/fonc.2021.723693","DOI":"10.3389\/fonc.2021.723693"},{"key":"10.32074\/1591-951X-747_ref54","doi-asserted-by":"crossref","unstructured":"Schaefgen B, Funk A, Sinn HP, et al. Does conventional specimen radiography after neoadjuvant chemotherapy of breast cancer help to reduce the rate of second surgeries? Breast Cancer Res Treat 2022;191:589-598. https:\/\/doi.org\/10.1007\/s10549-021-06466-3","DOI":"10.1007\/s10549-021-06466-3"},{"key":"10.32074\/1591-951X-747_ref55","doi-asserted-by":"crossref","unstructured":"Choi M, Park YH, Ahn JS, et al. Evaluation of pathologic complete response in breast cancer patients treated with neoadjuvant chemotherapy: experience in a single institution over a 10-year period. J Pathol Transl Med 2017;51:69-78. https:\/\/doi.org\/10.4132\/jptm.2016.10.05","DOI":"10.4132\/jptm.2016.10.05"},{"key":"10.32074\/1591-951X-747_ref56","doi-asserted-by":"crossref","unstructured":"Invernizzi M, de Sire A, Venetis K, et al. Quality of Life interventions in breast cancer survivors: state of the art in targeted rehabilitation strategies. Anticancer Agents Med Chem 2022;22:801-810. https:\/\/doi.org\/10.2174\/1871520621666210609095602","DOI":"10.2174\/1871520621666210609095602"},{"key":"10.32074\/1591-951X-747_ref57","doi-asserted-by":"crossref","unstructured":"Sunilkumar MM, Finni CG, Lijimol AS, et al. Health-related suffering and palliative care in breast cancer. Curr Breast Cancer Rep 2021;1-6. https:\/\/doi.org\/10.1007\/s12609-021-00431-1","DOI":"10.1007\/s12609-021-00431-1"},{"key":"10.32074\/1591-951X-747_ref58","doi-asserted-by":"crossref","unstructured":"Nardin S, Mora E, Varughese FM, et al. Breast cancer survivorship, quality of life, and late toxicities. Front Oncol 2020;10:864. https:\/\/doi.org\/10.3389\/fonc.2020.00864","DOI":"10.3389\/fonc.2020.00864"},{"key":"10.32074\/1591-951X-747_ref59","doi-asserted-by":"crossref","unstructured":"Madigan LI, Dinh P, Graham JD. Neoadjuvant endocrine therapy in locally advanced estrogen or progesterone receptor-positive breast cancer: determining the optimal endocrine agent and treatment duration in postmenopausal women-a literature review and proposed guidelines. Breast Cancer Res 2020;22:77. https:\/\/doi.org\/10.1186\/s13058-020-01314-6","DOI":"10.1186\/s13058-020-01314-6"}],"container-title":["Pathologica"],"original-title":[],"link":[{"URL":"https:\/\/www.pathologica.it\/article\/view\/747","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T13:26:52Z","timestamp":1730813212000},"score":1,"resource":{"primary":{"URL":"https:\/\/old.pathologica.it\/article\/view\/747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":59,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,4]]}},"URL":"https:\/\/doi.org\/10.32074\/1591-951x-747","relation":{},"ISSN":["1591-951X"],"issn-type":[{"value":"1591-951X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4]]},"article-number":"11"}}